$CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov

$clov Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000180117024000064 Filed on March 14, 2024

Income Statement

Concept	2023 Q4	2023	2022
Revenue	$510.3M	$2.034B	$3.477B
YoY Change	-43.23%	-41.5%	136.19%
Cost Of Revenue		$1.776B	$3.454B
YoY Change		-48.57%	122.67%
Gross Profit		$257.3M	$22.74M
YoY Change		1031.88%	-128.71%
Gross Profit Margin		12.65%	0.65%
Selling, General & Admin	$109.9M	$444.7M	$486.6M
YoY Change	-11.6%	-8.61%	9.17%
% of Gross Profit		172.82%	2140.5%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$674.0K	$400.0K	$400.0K
YoY Change	-180.14%	0.0%	33.33%
% of Gross Profit		0.16%	1.76%
Operating Expenses	$557.9M	$2.242B	$3.848B
YoY Change	-44.54%	-41.72%	82.44%
Operating Profit		-$208.5M	-$370.9M
YoY Change		-43.78%	-41.77%
Interest Expense	-$4.812M	$7.000K	$1.333M
YoY Change	2235.92%	-99.47%	-58.72%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	-$30.00K
YoY Change	-100.0%	-100.0%	-99.78%
Pretax Income	-$70.47M	-$213.4M	-$338.8M
YoY Change	-16.15%	-37.03%	-42.35%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$70.47M	-$213.4M	-$338.8M
YoY Change	-16.15%	-37.03%	-42.35%
Net Earnings / Revenue	-13.81%	-10.49%	-9.75%
Basic Earnings Per Share		-$0.44	-$0.71
Diluted Earnings Per Share	-$0.15	-$0.44	-$0.71
COMMON SHARES
Basic Shares Outstanding		482.2M shares	476.2M shares
Diluted Shares Outstanding		482.2M shares	476.2M shares

Balance Sheet

Concept	2023 Q4	2023	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$223.6M	$298.3M	$435.3M
YoY Change	-23.77%	-31.46%	-30.68%
Cash & Equivalents	$122.9M	$122.9M	$103.8M
Short-Term Investments	$100.7M	$175.5M	$331.5M
Other Short-Term Assets	$1.404M	$37.90M	$42.58M
YoY Change	-65.27%	-10.99%	-31.72%
Inventory
Prepaid Expenses	$14.42M
Receivables
Other Receivables
Total Short-Term Assets	$428.0M	$428.0M	$625.0M
YoY Change	-31.52%	-31.52%	-16.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.082M	$8.464M	$9.778M
YoY Change	-11.66%	-13.44%	27.75%
Goodwill	$0.00
YoY Change	-100.0%
Intangibles
YoY Change
Long-Term Investments	$121.0M	$121.0M	$138.1M
YoY Change	-12.39%	-12.39%	-21.5%
Other Assets	$10.25M	$10.25M	$15.74M
YoY Change	-34.88%	-34.88%	50.83%
Total Long-Term Assets	$142.7M	$142.7M	$183.6M
YoY Change	-22.29%	-22.29%	-7.38%
TOTAL ASSETS
Total Short-Term Assets	$428.0M	$428.0M	$625.0M
Total Long-Term Assets	$142.7M	$142.7M	$183.6M
Total Assets	$570.7M	$570.7M	$808.6M
YoY Change	-29.43%	-29.43%	-14.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$37.18M	$37.18M	$32.45M
YoY Change	14.61%	14.61%	15.34%
Accrued Expenses	$22.73M	$22.73M	$25.79M
YoY Change	-11.88%	-11.88%	41.65%
Deferred Revenue	$3.099M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$261.1M	$261.1M	$440.7M
YoY Change	-40.74%	-40.74%	18.26%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$20.16M	$23.16M	$20.23M
YoY Change	24.52%	14.52%	6.87%
Total Long-Term Liabilities	$20.16M	$23.16M	$20.23M
YoY Change	24.52%	14.52%	-47.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$261.1M	$261.1M	$440.7M
Total Long-Term Liabilities	$20.16M	$23.16M	$20.23M
Total Liabilities	$284.3M	$284.3M	$460.9M
YoY Change	-38.32%	-38.32%	10.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.160B
YoY Change	10.44%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$286.4M	$286.4M	$347.7M
YoY Change
Total Liabilities & Shareholders Equity	$570.7M	$570.7M	$808.6M
YoY Change	-29.43%	-29.43%	-14.95%

Cashflow Statement

Concept	2023 Q4	2023	2022
OPERATING ACTIVITIES
Net Income	-$70.47M	-$213.4M	-$338.8M
YoY Change	-16.15%	-37.03%	-42.35%
Depreciation, Depletion And Amortization	$674.0K	$400.0K	$400.0K
YoY Change	-180.14%	0.0%	33.33%
Cash From Operating Activities	-$229.3M	-$115.9M	-$203.9M
YoY Change	9.52%	-43.18%	-27.77%
INVESTING ACTIVITIES
Capital Expenditures	-$264.0K	$584.0K	$4.467M
YoY Change	-106.81%	-86.93%	517.84%
Acquisitions		$0.00	$16.20M
YoY Change		-100.0%
Other Investing Activities	$83.40M	$140.6M	$99.60M
YoY Change	404.43%	41.16%	-122.91%
Cash From Investing Activities	$83.66M	$140.0M	$95.13M
YoY Change	561.05%	47.18%	-121.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$6.220M	$6.362M
YoY Change		-2.23%	-102.24%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-29.62M	-$33.86M	-$4.962M
YoY Change	-52987.5%	582.41%	-100.54%
NET CHANGE
Cash From Operating Activities	-229.3M	-$115.9M	-$203.9M
Cash From Investing Activities	83.66M	$140.0M	$95.13M
Cash From Financing Activities	-29.62M	-$33.86M	-$4.962M
Net Change In Cash	-175.3M	-$9.719M	-$113.8M
YoY Change	-10.88%	-91.46%	-154.79%
FREE CASH FLOW
Cash From Operating Activities	-$229.3M	-$115.9M	-$203.9M
Capital Expenditures	-$264.0K	$584.0K	$4.467M
Free Cash Flow	-$229.0M	-$116.5M	-$208.4M
YoY Change	7.4%	-44.12%	-26.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Revenues Revenues	2033720000	usd
CY2023	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	1776388000	usd
CY2022	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	3453952000	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	257157000	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	278725000	usd
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense	260458000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	187571000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	207917000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	185287000	usd
CY2023	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-7239000	usd
CY2022	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-93517000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2509000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1187000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1246000	usd
CY2023	us-gaap	Restructuring Costs RestructuringCosts	9931000	usd
CY2022	us-gaap	Restructuring Costs RestructuringCosts	0	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	2242262000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	3848334000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-208542000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-371647000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-636992000	usd
CY2023	us-gaap	Interest Expense InterestExpense	7000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	30000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-4726000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	9217000	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	482176127	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	482176127	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	476244262	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	476244262	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	412922424	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	412922424	shares
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	7004000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7440000	usd
CY2021	us-gaap	Restructuring Costs RestructuringCosts	0	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	2108988000	usd
CY2021	us-gaap	Interest Expense InterestExpense	3193000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13717000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-213361000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-339567000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-587756000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.42
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023	clov	Deferred Policy Acquisition Costs Amortization Expense Premium Deficiency Reserve DeferredPolicyAcquisitionCostsAmortizationExpensePremiumDeficiencyReserve	0	usd
CY2022	clov	Deferred Policy Acquisition Costs Amortization Expense Premium Deficiency Reserve DeferredPolicyAcquisitionCostsAmortizationExpensePremiumDeficiencyReserve	0	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001801170
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Entity Registrant Name EntityRegistrantName	CLOVER HEALTH INVESTMENTS, CORP. /DE
CY2023	us-gaap	Fair Value Asset Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List FairValueAssetRecurringBasisStillHeldUnrealizedGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#FairValueAdjustmentOfWarrants
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39252
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1515192
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3401 Mallory Lane
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Franklin
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37067
CY2023	dei	City Area Code CityAreaCode	201
CY2023	dei	Local Phone Number LocalPhoneNumber	432-2133
CY2023	dei	Security12g Title Security12gTitle	Class A Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	CLOV
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	360169848	usd
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	New York, New York
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122863000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103791000	usd
CY2023Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	12218000	usd
CY2022Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	41457000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	101412000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	193300000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	100702000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	189498000	usd
CY2023Q4	us-gaap	Debt Securities Held To Maturity Fair Value Current DebtSecuritiesHeldToMaturityFairValueCurrent	6778000	usd
CY2022Q4	us-gaap	Debt Securities Held To Maturity Fair Value Current DebtSecuritiesHeldToMaturityFairValueCurrent	15000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	6902000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	15000	usd
CY2023Q4	clov	Accrued Retrospective Premiums Current AccruedRetrospectivePremiumsCurrent	22076000	usd
CY2022Q4	clov	Accrued Retrospective Premiums Current AccruedRetrospectivePremiumsCurrent	20387000	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	16666000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	23596000	usd
CY2023Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	64164000	usd
CY2022Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	70607000	usd
CY2023Q4	clov	Non Insurance Receivable NonInsuranceReceivable	10926000	usd
CY2022Q4	clov	Non Insurance Receivable NonInsuranceReceivable	52955000	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	55631000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	100502000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	14418000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18146000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1404000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4043000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	427970000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	624997000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	121868000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	142940000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	120208000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	137368000	usd
CY2023Q4	us-gaap	Debt Securities Held To Maturity Fair Value Noncurrent DebtSecuritiesHeldToMaturityFairValueNoncurrent	692000	usd
CY2022Q4	us-gaap	Debt Securities Held To Maturity Fair Value Noncurrent DebtSecuritiesHeldToMaturityFairValueNoncurrent	636000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	793000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	742000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5082000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5753000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3382000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4025000	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	2990000	usd
CY2022Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	20000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10246000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15735000	usd
CY2023Q4	us-gaap	Assets Assets	570671000	usd
CY2022Q4	us-gaap	Assets Assets	808620000	usd
CY2023Q4	us-gaap	Assumed Liability For Unpaid Claims And Claims Adjustment Expense AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	138593000	usd
CY2022Q4	us-gaap	Assumed Liability For Unpaid Claims And Claims Adjustment Expense AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	141947000	usd
CY2023Q4	clov	Non Insurance Performance Year Obligation Current NonInsurancePerformanceYearObligationCurrent	15568000	usd
CY2022Q4	clov	Non Insurance Performance Year Obligation Current NonInsurancePerformanceYearObligationCurrent	73844000	usd
CY2023Q4	clov	Non Insurance Payable Current NonInsurancePayableCurrent	41565000	usd
CY2022Q4	clov	Non Insurance Payable Current NonInsurancePayableCurrent	148191000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	37184000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	32445000	usd
CY2023Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	21061000	usd
CY2022Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	23962000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3099000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1665000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1827000	usd
CY2023Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	0	usd
CY2022Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	7239000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	261115000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	431507000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2998000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4033000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20164000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16193000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	284277000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	451733000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2461238000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2319157000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2370000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9374000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2159794000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1946433000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7912750	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2072752	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	12729000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	6509000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	286394000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	356887000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	570671000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	808620000	usd
CY2023	us-gaap	Ceded Premiums Earned CededPremiumsEarned	444000	usd
CY2022	us-gaap	Ceded Premiums Earned CededPremiumsEarned	470000	usd
CY2021	us-gaap	Ceded Premiums Earned CededPremiumsEarned	489000	usd
CY2023	us-gaap	Premiums Earned Net PremiumsEarnedNet	1235769000	usd
CY2022	us-gaap	Premiums Earned Net PremiumsEarnedNet	1084869000	usd
CY2021	us-gaap	Premiums Earned Net PremiumsEarnedNet	799414000	usd
CY2023	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	773177000	usd
CY2022	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	2380135000	usd
CY2021	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	667639000	usd
CY2023	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	24774000	usd
CY2022	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	11683000	usd
CY2021	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	4943000	usd
CY2022	us-gaap	Revenues Revenues	3476687000	usd
CY2021	us-gaap	Revenues Revenues	1471996000	usd
CY2021	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	1551178000	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	15945000	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2021	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	110628000	usd
CY2023	us-gaap	Other General Expense OtherGeneralExpense	0	usd
CY2022	us-gaap	Other General Expense OtherGeneralExpense	70000	usd
CY2021	us-gaap	Other General Expense OtherGeneralExpense	191000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	86000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-900000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-66146000	usd
CY2022	us-gaap	Interest Expense InterestExpense	1333000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	23326000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.42
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1944000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-206357000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-347007000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-589700000	usd
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	139444346	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	447747000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-613193000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6144000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	163723000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1944000	usd
CY2021	clov	Temporary Equity Shares Conversion Of Convertible Securities TemporaryEquitySharesConversionOfConvertibleSecurities	139444346	shares
CY2021	clov	Temporary Equity Value Conversion Of Convertible Securities TemporaryEquityValueConversionOfConvertibleSecurities	447747000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	447747000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	16059000	usd
CY2021	clov	Stock Issued During Period Value Business Combination And Offering StockIssuedDuringPeriodValueBusinessCombinationAndOffering	666241000	usd
CY2021	clov	Conversion From Class B To Class A Common Stock Amount ConversionFromClassBToClassACommonStockAmount	0	usd
CY2021	clov	Conversion From Class A To Class B Common Stock ConversionFromClassAToClassBCommonStock	0	usd
CY2021	clov	Capital Contribution For Extinguishment Of Debt CapitalContributionForExtinguishmentOfDebt	126795000	usd
CY2021	clov	Acquisition Of Public And Private Placement Warrants AcquisitionOfPublicAndPrivatePlacementWarrants	147582000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	283775000	usd
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	147000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-587756000	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	540040000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1400000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	164305000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7440000	usd
CY2022	clov	Conversion From Class B To Class A Common Stock Amount ConversionFromClassBToClassACommonStockAmount	0	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	6362000	usd
CY2022	clov	Adjustments To Additional Paid In Capital And Accumulated Deficit From Seek Dissolution AdjustmentsToAdditionalPaidInCapitalAndAccumulatedDeficitFromSeekDissolution	-735000	usd
CY2022	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	3903000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-339567000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	356887000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1150000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	140931000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	2000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	7004000	usd
CY2023	clov	Conversion From Class B To Class A Common Stock Amount ConversionFromClassBToClassACommonStockAmount	1000	usd
CY2023	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	6220000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-213361000	usd
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	286394000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-213361000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-339567000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-587756000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2509000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1187000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1246000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	30000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13717000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	140931000	usd
CY2021	clov	Increase Decrease In Fair Value Adjustment Of Warrants IncreaseDecreaseInFairValueAdjustmentOfWarrants	-66146000	usd
CY2022	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	-1503000	usd
CY2021	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	200000	usd
CY2021	clov	Realized Investment Losses Gains RealizedInvestmentLossesGains	-53000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	23326000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-4726000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	9217000	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	15945000	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2023	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-7239000	usd
CY2022	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-93517000	usd
CY2021	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	110628000	usd
CY2023	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-1689000	usd
CY2022	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	14536000	usd
CY2021	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-94000	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-6930000	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	8988000	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	2914000	usd
CY2023	us-gaap	Increase Decrease In Reinsurance Recoverable IncreaseDecreaseInReinsuranceRecoverable	0	usd
CY2022	us-gaap	Increase Decrease In Reinsurance Recoverable IncreaseDecreaseInReinsuranceRecoverable	0	usd
CY2021	us-gaap	Increase Decrease In Reinsurance Recoverable IncreaseDecreaseInReinsuranceRecoverable	96000	usd
CY2023	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-44871000	usd
CY2022	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	89846000	usd
CY2021	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	10656000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-3728000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3415000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	6863000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1828000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1204000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4296000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6443000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22565000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9297000	usd
CY2023	clov	Increase Decrease In Non Insurance Receivable IncreaseDecreaseInNonInsuranceReceivable	-42029000	usd
CY2022	clov	Increase Decrease In Non Insurance Receivable IncreaseDecreaseInNonInsuranceReceivable	40785000	usd
CY2021	clov	Increase Decrease In Non Insurance Receivable IncreaseDecreaseInNonInsuranceReceivable	12170000	usd
CY2023	clov	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	643000	usd
CY2022	clov	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	1984000	usd
CY2021	clov	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	3591000	usd
CY2023	clov	Increase Decrease In Unpaid Claims IncreaseDecreaseInUnpaidClaims	-3557000	usd
CY2022	clov	Increase Decrease In Unpaid Claims IncreaseDecreaseInUnpaidClaims	2589000	usd
CY2021	clov	Increase Decrease In Unpaid Claims IncreaseDecreaseInUnpaidClaims	36948000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4739000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	7635000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5307000	usd
CY2023	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-2901000	usd
CY2022	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	8784000	usd
CY2021	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	11169000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3099000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2023	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	usd
CY2022	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	usd
CY2021	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-68000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	4502000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2468000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	979000	usd
CY2023	clov	Increase Decrease In Performance Year Obligation IncreaseDecreaseInPerformanceYearObligation	-58276000	usd
CY2022	clov	Increase Decrease In Performance Year Obligation IncreaseDecreaseInPerformanceYearObligation	36953000	usd
CY2021	clov	Increase Decrease In Performance Year Obligation IncreaseDecreaseInPerformanceYearObligation	36891000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	147000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-33861000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	77460000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	925393000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9719000	usd
CY2023	clov	Increase Decrease In Non Insurance Payable IncreaseDecreaseInNonInsurancePayable	-106626000	usd
CY2022	clov	Increase Decrease In Non Insurance Payable IncreaseDecreaseInNonInsurancePayable	110418000	usd
CY2021	clov	Increase Decrease In Non Insurance Payable IncreaseDecreaseInNonInsurancePayable	37773000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1197000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2671000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4331000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-115871000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-286348000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-282326000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	175567000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	369396000	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	876252000	usd
CY2023	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	60436000	usd
CY2022	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	13348000	usd
CY2021	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	126862000	usd
CY2023	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	255728000	usd
CY2022	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	472098000	usd
CY2021	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	314666000	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	16200000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	584000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4467000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	723000	usd
CY2023	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	usd
CY2022	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	250000	usd
CY2021	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	140013000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	95133000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-435447000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	30925000	usd
CY2023	clov	Payments Proceeds Of Restricted Cash Related To Bonds Deposits And Escrow Accounts PaymentsProceedsOfRestrictedCashRelatedToBondsDepositsAndEscrowAccounts	-28791000	usd
CY2022	clov	Payments Proceeds Of Restricted Cash Related To Bonds Deposits And Escrow Accounts PaymentsProceedsOfRestrictedCashRelatedToBondsDepositsAndEscrowAccounts	82422000	usd
CY2021	clov	Payments Proceeds Of Restricted Cash Related To Bonds Deposits And Escrow Accounts PaymentsProceedsOfRestrictedCashRelatedToBondsDepositsAndEscrowAccounts	0	usd
CY2023	clov	Proceeds From Issuance Of Common Stock Net Of Early Exercise Liability ProceedsFromIssuanceOfCommonStockNetOfEarlyExerciseLiability	1150000	usd
CY2022	clov	Proceeds From Issuance Of Common Stock Net Of Early Exercise Liability ProceedsFromIssuanceOfCommonStockNetOfEarlyExerciseLiability	1400000	usd
CY2021	clov	Proceeds From Issuance Of Common Stock Net Of Early Exercise Liability ProceedsFromIssuanceOfCommonStockNetOfEarlyExerciseLiability	6144000	usd
CY2023	clov	Proceeds From Reverse Capitalization Net Of Transaction Costs ProceedsFromReverseCapitalizationNetOfTransactionCosts	0	usd
CY2022	clov	Proceeds From Reverse Capitalization Net Of Transaction Costs ProceedsFromReverseCapitalizationNetOfTransactionCosts	0	usd
CY2021	clov	Proceeds From Reverse Capitalization Net Of Transaction Costs ProceedsFromReverseCapitalizationNetOfTransactionCosts	666241000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	390000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	283775000	usd
CY2023	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	usd
CY2022	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	usd
CY2021	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	85000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	6220000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	6362000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-113755000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	207620000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	186213000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299968000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92348000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	176494000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	186213000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299968000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122863000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103791000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	299968000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	53631000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	82422000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	176494000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	186213000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299968000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1677000	usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	447747000	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	16059000	usd
CY2023	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0	usd
CY2022	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0	usd
CY2021	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	126795000	usd
CY2023	clov	Activities From Seek Dissolution ActivitiesFromSeekDissolution	0	usd
CY2022	clov	Activities From Seek Dissolution ActivitiesFromSeekDissolution	735000	usd
CY2021	clov	Activities From Seek Dissolution ActivitiesFromSeekDissolution	0	usd
CY2023	clov	Issuance Of Common Stock Related To Warrants Exercised IssuanceOfCommonStockRelatedToWarrantsExercised	0	usd
CY2022	clov	Issuance Of Common Stock Related To Warrants Exercised IssuanceOfCommonStockRelatedToWarrantsExercised	0	usd
CY2021	clov	Issuance Of Common Stock Related To Warrants Exercised IssuanceOfCommonStockRelatedToWarrantsExercised	97782000	usd
CY2023	clov	Acquisition Of Public And Private Warrants AcquisitionOfPublicAndPrivateWarrants	0	usd
CY2022	clov	Acquisition Of Public And Private Warrants AcquisitionOfPublicAndPrivateWarrants	0	usd
CY2021	clov	Acquisition Of Public And Private Warrants AcquisitionOfPublicAndPrivateWarrants	147582000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	81283000	usd
CY2023	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	usd
CY2022	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	642000	usd
CY2021	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1076000	usd
CY2023	us-gaap	Transfer To Investments TransferToInvestments	0	usd
CY2022	us-gaap	Transfer To Investments TransferToInvestments	8644000	usd
CY2021	us-gaap	Transfer To Investments TransferToInvestments	0	usd
CY2023	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	0	usd
CY2022	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	3903000	usd
CY2021	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	0	usd
CY2023	clov	Conversion Of Convertible Note To Preferred Stock ConversionOfConvertibleNoteToPreferredStock	0	usd
CY2022	clov	Conversion Of Convertible Note To Preferred Stock ConversionOfConvertibleNoteToPreferredStock	250000	usd
CY2021	clov	Conversion Of Convertible Note To Preferred Stock ConversionOfConvertibleNoteToPreferredStock	0	usd
CY2023Q4	clov	Direct Contracting Shared Savings And Losses Percent DirectContractingSharedSavingsAndLossesPercent	1.000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the amounts reported in the consolidated financial statements and the accompanying notes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The areas involving the most significant use of estimates are the amounts of incurred but not reported claims. Many factors can cause actual outcomes to deviate from these assumptions and estimates, such as changes in economic conditions, changes in government healthcare policy, advances in medical technology, changes in treatment patterns, and changes in average lifespan. Accordingly, the Company cannot determine with precision the ultimate amounts that it will pay for, or the timing of payment of actual claims, or whether the assets supporting the liabilities will grow to the level the Company assumes prior to payment of claims. If the Company's actual experience is different from its assumptions or estimates, the Company's reserves may prove inadequate. As a result, the Company would incur a charge to operations in the period in which it determines such a shortfall exists, which could have a material adverse effect on the Company's business, results of operations, and financial condition. Other areas involving significant estimates include risk adjustment provisions related to Medicare contracts and the valuation of the Company's investment securities, goodwill and other intangible assets, reinsurance, premium deficiency reserve, warrants, embedded derivative related to convertible securities, stock-based compensation, recoveries from third parties for coordination of benefits, Direct Contracting benchmark, specifically cost trend and risk score estimates that can develop over time, and final determination of medical cost adjustment pools.</span></div>
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the prior years' audited Consolidated Statements of Cash Flows have been reclassified to conform to the current year's presentation, primarily related to Surety bonds and deposits and Change in restricted cash related to Surety Bonds, Deposits, and Escrow accounts. These reclassifications had no material effect on the previously reported Consolidated Financial Statements.</span></div>
CY2022Q1	clov	Decrease In Accumulated Deficit DecreaseInAccumulatedDeficit	700000	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1616000000	usd
CY2022Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	7239000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	431507000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	451733000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1946433000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	356887000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	808620000	usd
CY2021Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	109905000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	371901000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	410764000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1616015000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	540040000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	950804000	usd
CY2023	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-7239000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	2242262000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-208542000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-213361000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2022	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-93517000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	3848334000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-371647000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-339567000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q4	us-gaap	Financing Receivable Collectively Evaluated For Impairment FinancingReceivableCollectivelyEvaluatedForImpairment	0	usd
CY2021Q4	us-gaap	Financing Receivable Collectively Evaluated For Impairment FinancingReceivableCollectivelyEvaluatedForImpairment	0	usd
CY2023Q4	us-gaap	Financing Receivable Collectively Evaluated For Impairment FinancingReceivableCollectivelyEvaluatedForImpairment	0	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of Cash and cash equivalents. Cash and cash equivalents are held with financial institutions of high quality. Balances may exceed the amount of insurance provided on such balances.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ceding of insurance does not legally discharge the Company from its primary liability for the full amount of the policy coverage, and therefore the Company will be required to pay the loss and bear collection risk if the reinsurer fails to meet its obligations under the reinsurance agreement. To minimize exposure to significant losses from reinsurance insolvencies, the Company evaluates the financial condition of its reinsurers and monitors concentrations of credit risk with its reinsurers.</span></div>
CY2023	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reportingunit
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11700000	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4200000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q4	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	0	usd
CY2023Q4	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	0	usd
CY2023Q4	us-gaap	Investments Investments	230975000	usd
CY2023Q4	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	878000	usd
CY2023Q4	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3473000	usd
CY2023Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	228380000	usd
CY2022Q4	us-gaap	Investments Investments	336997000	usd
CY2022Q4	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	48000	usd
CY2022Q4	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9528000	usd
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	327517000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	6902000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	6778000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	101412000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	100702000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	682000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	599000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	121868000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	120208000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount	0	usd
CY2023Q4	us-gaap	Held To Maturity Securities Debt Maturities After Five Through Ten Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0	usd
CY2023Q4	us-gaap	Held To Maturity Securities Debt Maturities After Ten Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterTenYearsNetCarryingAmount	111000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Debt Maturities After Ten Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterTenYearsFairValue	93000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	0	usd
CY2023Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	7695000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	7470000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	223280000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	220910000	usd
CY2023	us-gaap	Net Investment Income NetInvestmentIncome	18374000	usd
CY2022	us-gaap	Net Investment Income NetInvestmentIncome	7543000	usd
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	544000	usd
CY2023Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position Year One Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPositionYearOneFairValue	73591000	usd
CY2023Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position Year One Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPositionYearOneAccumulatedLoss	207000	usd
CY2023Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position12 Months Or Longer Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPosition12MonthsOrLongerFairValue	66645000	usd
CY2023Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	3266000	usd
CY2023Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionFairValue	140236000	usd
CY2023Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionAccumulatedLoss	3473000	usd
CY2023Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions Year One DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositionsYearOne	69	position
CY2023Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions12 Months Or Longer DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions12MonthsOrLonger	27	position
CY2023Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions	96	position
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position Year One Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPositionYearOneFairValue	142553000	usd
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position Year One Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPositionYearOneAccumulatedLoss	1380000	usd
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position12 Months Or Longer Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPosition12MonthsOrLongerFairValue	147757000	usd
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	8148000	usd
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionFairValue	290310000	usd
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionAccumulatedLoss	9528000	usd
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions Year One DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositionsYearOne	92	position
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions12 Months Or Longer DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions12MonthsOrLonger	24	position
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions	116	position
CY2022Q4	us-gaap	Debt Securities Held To Maturity Allowance For Credit Loss DebtSecuritiesHeldToMaturityAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Held To Maturity Allowance For Credit Loss DebtSecuritiesHeldToMaturityAllowanceForCreditLoss	0	usd
CY2023	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	60436000	usd
CY2022	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	13348000	usd
CY2021	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	126862000	usd
CY2023	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	255728000	usd
CY2022	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	472098000	usd
CY2021	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	314666000	usd
CY2023	clov	Short Term Investments And Available For Sale Securities Gross Realized Gains ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedGains	39000	usd
CY2022	clov	Short Term Investments And Available For Sale Securities Gross Realized Gains ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedGains	7000	usd
CY2021	clov	Short Term Investments And Available For Sale Securities Gross Realized Gains ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedGains	24000	usd
CY2023	clov	Short Term Investments And Available For Sale Securities Gross Realized Losses ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedLosses	19000	usd
CY2022	clov	Short Term Investments And Available For Sale Securities Gross Realized Losses ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedLosses	274000	usd
CY2021	clov	Short Term Investments And Available For Sale Securities Gross Realized Losses ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedLosses	77000	usd
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	20000	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-267000	usd
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-53000	usd
CY2023Q4	us-gaap	Deposits Deposits	14700000	usd
CY2022Q4	us-gaap	Deposits Deposits	14300000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	221724000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	327766000	usd
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.10
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2023Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	64200000	usd
CY2022Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	70600000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9665000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8064000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4583000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2311000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5082000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5753000	usd
CY2023	us-gaap	Depreciation Depreciation	400000	usd
CY2022	us-gaap	Depreciation Depreciation	400000	usd
CY2021	us-gaap	Depreciation Depreciation	300000	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1000000	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	800000	usd
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	200000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	1243000	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	10506000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	11749000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11749000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11700000	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2023	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity within the liability for Unpaid claims, including claims adjustment expenses, for the years ended December 31, 2023 and 2022, respectively, is summarized as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross and net balance, beginning of period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996,158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023,355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,158 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892,495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,453 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982,953 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross and net balance, end of period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt double #ffffff;border-top:0.25pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,395 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes amounts due to related parties. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Differs from the total Unpaid claims amount reported on the Consolidated Balance Sheets due to the fact the figure here excludes unpaid claims for the Company's Non-Insurance operations of $2.9 million and $6.1 million at December 31, 2023 and 2022, respectively.</span></div>
CY2022Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	137395000	usd
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	136317000	usd
CY2023	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	996158000	usd
CY2022	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	1023355000	usd
CY2023	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-9000000	usd
CY2022	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-39324000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	987158000	usd
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	984031000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	865930000	usd
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	892495000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	121523000	usd
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	90458000	usd
CY2023	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	987453000	usd
CY2022	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	982953000	usd
CY2023Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	137100000	usd
CY2022Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	137395000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	121500000	usd
CY2023	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-9000000	usd
CY2022	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-39300000	usd
CY2023	clov	Ratio Of Current Year Medical Claims Paid As A Percent Of Current Year Net Medical Claims RatioOfCurrentYearMedicalClaimsPaidAsAPercentOfCurrentYearNetMedicalClaims	0.869
CY2022	clov	Ratio Of Current Year Medical Claims Paid As A Percent Of Current Year Net Medical Claims RatioOfCurrentYearMedicalClaimsPaidAsAPercentOfCurrentYearNetMedicalClaims	0.872
CY2021Q4	us-gaap	Shortduration Insurance Contracts Incurred Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet	2138604000	usd
CY2022Q4	us-gaap	Shortduration Insurance Contracts Incurred Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet	3122689000	usd
CY2023Q4	us-gaap	Shortduration Insurance Contracts Incurred Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet	3845797000	usd
CY2023Q4	us-gaap	Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet	137100000	usd
CY2023Q4	us-gaap	Shortduration Insurance Contracts Number Of Reported Claims ShortdurationInsuranceContractsNumberOfReportedClaims	13991051000	claim
CY2021Q4	us-gaap	Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet	2002287000	usd
CY2022Q4	us-gaap	Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet	2985295000	usd
CY2023Q4	us-gaap	Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet	3708697000	usd
CY2023Q4	us-gaap	Shortduration Insurance Contracts Incurred Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet	3845797000	usd
CY2023Q4	us-gaap	Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet	3708697000	usd
CY2023Q4	us-gaap	Shortduration Insurance Contracts Liability For Unpaid Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet	137100000	usd
CY2023	clov	Reinsurance Excess Loss Coverage Threshold Per Covered Person ReinsuranceExcessLossCoverageThresholdPerCoveredPerson	400000	usd
CY2022	clov	Reinsurance Excess Loss Coverage Threshold Per Covered Person ReinsuranceExcessLossCoverageThresholdPerCoveredPerson	600000	usd
CY2021	clov	Reinsurance Excess Loss Coverage Threshold Per Covered Person ReinsuranceExcessLossCoverageThresholdPerCoveredPerson	600000	usd
CY2023Q4	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	0	usd
CY2022Q4	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	0	usd
CY2023Q4	us-gaap	Prepaid Reinsurance Premiums PrepaidReinsurancePremiums	0	usd
CY2022Q4	us-gaap	Prepaid Reinsurance Premiums PrepaidReinsurancePremiums	0	usd
CY2023Q4	us-gaap	Reinsurance Recoverables ReinsuranceRecoverables	46000	usd
CY2022Q4	us-gaap	Reinsurance Recoverables ReinsuranceRecoverables	500000	usd
CY2023Q4	clov	Coinsurance Percentage CoinsurancePercentage	1
CY2023Q4	clov	Life Insurance Reserves Fully Coinsured By Third Party LifeInsuranceReservesFullyCoinsuredByThirdParty	5100000	usd
CY2022Q4	clov	Life Insurance Reserves Fully Coinsured By Third Party LifeInsuranceReservesFullyCoinsuredByThirdParty	5400000	usd
CY2023Q4	clov	Life Insurance Reserves Coinsurance Percentage LifeInsuranceReservesCoinsurancePercentage	1
CY2023Q4	clov	Annuity Reserve Fully Coinsured To Third Party AnnuityReserveFullyCoinsuredToThirdParty	900000	usd
CY2022Q4	clov	Annuity Reserve Fully Coinsured To Third Party AnnuityReserveFullyCoinsuredToThirdParty	900000	usd
CY2023Q4	clov	Annuity Reserves Transfer Of Risk Percentage AnnuityReservesTransferOfRiskPercentage	1
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	373800000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	44800000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	44800000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1346000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2651000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	4515000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	51000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	56000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	515000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	45000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	256000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	1124000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	2727000	usd
CY2023	us-gaap	Lease Cost LeaseCost	1141000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1583000	usd
CY2021	us-gaap	Lease Cost LeaseCost	2348000	usd
CY2023	clov	Cash Paid For Amounts Included In The Measurement Of Lease Liabilities CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities	1907000	usd
CY2022	clov	Cash Paid For Amounts Included In The Measurement Of Lease Liabilities CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities	3340000	usd
CY2021	clov	Cash Paid For Amounts Included In The Measurement Of Lease Liabilities CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities	5248000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y2M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1031
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1065
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1036
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1737000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1265000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1155000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1190000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	303000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5650000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	987000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4663000	usd
CY2022	clov	Effective Income Tax Rate Reconciliation162m Limitation Amount EffectiveIncomeTaxRateReconciliation162mLimitationAmount	0	usd
CY2021	clov	Effective Income Tax Rate Reconciliation162m Limitation Amount EffectiveIncomeTaxRateReconciliation162mLimitationAmount	0	usd
CY2023	clov	Effective Income Tax Rate Reconciliation162m Limitation Amount EffectiveIncomeTaxRateReconciliation162mLimitationAmount	1488000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7912750	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2072752	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1.000
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.040
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.040
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1800000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1600000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1200000	usd
CY2023	us-gaap	Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage	1.000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	140931000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	164305000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	163723000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	436700000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.36
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	100000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	23319559	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	100000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.86
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M9D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	11300000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	39300000	usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	100000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-44806000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-71157000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-123429000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-59000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	usd
CY2023	clov	Effective Income Tax Rate Reconciliation Interest On Convertible Securities Discount Amount EffectiveIncomeTaxRateReconciliationInterestOnConvertibleSecuritiesDiscountAmount	0	usd
CY2022	clov	Effective Income Tax Rate Reconciliation Interest On Convertible Securities Discount Amount EffectiveIncomeTaxRateReconciliationInterestOnConvertibleSecuritiesDiscountAmount	0	usd
CY2021	clov	Effective Income Tax Rate Reconciliation Interest On Convertible Securities Discount Amount EffectiveIncomeTaxRateReconciliationInterestOnConvertibleSecuritiesDiscountAmount	2867000	usd
CY2023	clov	Effective Income Tax Rate Reconciliation Warrant Expense Amount EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount	18000	usd
CY2022	clov	Effective Income Tax Rate Reconciliation Warrant Expense Amount EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount	-189000	usd
CY2021	clov	Effective Income Tax Rate Reconciliation Warrant Expense Amount EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount	13905000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	27000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	21000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	26000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	16408000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	7989000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-5665000	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-221000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-30646000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	0	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-231000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	317000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-365000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	27376000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	93665000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	112661000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	320416000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	294335000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	66251000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	56743000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Unearned Premiums Reserve DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Unearned Premiums Reserve DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve	3442000	usd
CY2023Q4	clov	Deferred Tax Assets Unpaid Claim Reserve Discounting DeferredTaxAssetsUnpaidClaimReserveDiscounting	420000	usd
CY2022Q4	clov	Deferred Tax Assets Unpaid Claim Reserve Discounting DeferredTaxAssetsUnpaidClaimReserveDiscounting	384000	usd
CY2023Q4	clov	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	290000	usd
CY2022Q4	clov	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	1231000	usd
CY2023Q4	clov	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	1590000	usd
CY2022Q4	clov	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	1589000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5175000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	9927000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3601000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	800000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4692000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	398543000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	372343000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	396906000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	369530000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1637000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2813000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	672000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	845000	usd
CY2023Q4	clov	Deferred Tax Liabilities Nontaxable Gain On Deconsolidation Of Entity DeferredTaxLiabilitiesNontaxableGainOnDeconsolidationOfEntity	943000	usd
CY2022Q4	clov	Deferred Tax Liabilities Nontaxable Gain On Deconsolidation Of Entity DeferredTaxLiabilitiesNontaxableGainOnDeconsolidationOfEntity	1936000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	22000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	32000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1637000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2813000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1525400000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1401600000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1525400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	295100000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	1230300000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-213361000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-339567000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-587756000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-213361000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-339567000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-587756000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	482176127	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	482176127	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	476244262	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	476244262	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	412922424	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	412922424	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.42
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.42
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	114054590	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	106558941	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	81992991	shares
CY2023	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	0	usd
CY2022	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	0	usd
CY2023Q2	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	22000000	usd
CY2023Q2	clov	Litigation Settlement Insurance Proceeds LitigationSettlementInsuranceProceeds	19500000	usd
CY2023Q2	us-gaap	Escrow Deposit EscrowDeposit	7700000	usd
CY2023Q2	clov	Escrow Deposit Remaining Amount EscrowDepositRemainingAmount	14300000	usd
CY2021Q3	clov	Number Of Derivative Actions NumberOfDerivativeActions	2	action
CY2022Q3	clov	Number Of Derivative Actions NumberOfDerivativeActions	2	action
CY2023Q2	clov	Derivative Instruments Award Fees And Expenses DerivativeInstrumentsAwardFeesAndExpenses	2500000	usd
CY2023Q4	clov	Direct Contracting Risk Mitigation Maximum Percentage Of Performance Year Benchmark DirectContractingRiskMitigationMaximumPercentageOfPerformanceYearBenchmark	0.25
CY2023Q4	clov	Non Insurance Performance Year Obligation Current NonInsurancePerformanceYearObligationCurrent	15568000	usd
CY2022Q4	clov	Non Insurance Performance Year Obligation Current NonInsurancePerformanceYearObligationCurrent	73844000	usd
CY2023	clov	Non Insurance Performance Year Receivable Amortization NonInsurancePerformanceYearReceivableAmortization	751362000	usd
CY2022	clov	Non Insurance Performance Year Receivable Amortization NonInsurancePerformanceYearReceivableAmortization	2385116000	usd
CY2023	clov	Non Insurance Performance Year Obligation Amortization NonInsurancePerformanceYearObligationAmortization	751362000	usd
CY2022	clov	Non Insurance Performance Year Obligation Amortization NonInsurancePerformanceYearObligationAmortization	2385116000	usd
CY2023	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	773177000	usd
CY2022	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	2380135000	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023	us-gaap	Ceded Premiums Earned CededPremiumsEarned	444000	usd
CY2023	us-gaap	Premiums Earned Net PremiumsEarnedNet	1235769000	usd
CY2023	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	773177000	usd
CY2023	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	24774000	usd
CY2023	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	1776388000	usd
CY2023	us-gaap	Gross Profit GrossProfit	257332000	usd
CY2023Q4	us-gaap	Assets Assets	570671000	usd
CY2022	us-gaap	Ceded Premiums Earned CededPremiumsEarned	470000	usd
CY2022	us-gaap	Premiums Earned Net PremiumsEarnedNet	1084869000	usd
CY2022	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	2380135000	usd
CY2022	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	11683000	usd
CY2022	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	3453952000	usd
CY2022	us-gaap	Gross Profit GrossProfit	22735000	usd
CY2022Q4	us-gaap	Assets Assets	808620000	usd
CY2023	us-gaap	Gross Profit GrossProfit	257332000	usd
CY2022	us-gaap	Gross Profit GrossProfit	22735000	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	257157000	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	278725000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	187571000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	207917000	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	15945000	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2023	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-7239000	usd
CY2022	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-93517000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2509000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1187000	usd
CY2023	us-gaap	Restructuring Costs RestructuringCosts	9931000	usd
CY2022	us-gaap	Restructuring Costs RestructuringCosts	0	usd
CY2023	us-gaap	Other General Expense OtherGeneralExpense	0	usd
CY2022	us-gaap	Other General Expense OtherGeneralExpense	70000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	86000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-900000	usd
CY2023	us-gaap	Interest Expense InterestExpense	7000	usd
CY2022	us-gaap	Interest Expense InterestExpense	1333000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	30000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-4726000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	9217000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	23326000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-213361000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-339567000	usd
CY2023Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.10
CY2023	us-gaap	Restructuring Charges RestructuringCharges	9931000	usd
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	usd
CY2023	clov	Restructuring Charges Excluding Exit Project RestructuringChargesExcludingExitProject	9821000	usd
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	4650000	usd
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	5171000	usd
CY2023Q4	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	9821000	usd
CY2023Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Balance StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance	187400000	usd
CY2022Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Balance StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance	141400000	usd
CY2023Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Required StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired	113700000	usd
CY2022Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Required StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired	120600000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	7912750	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2072752	shares
CY2023	clov	Activities From Seek Dissolution ActivitiesFromSeekDissolution	0	usd
CY2022	clov	Activities From Seek Dissolution ActivitiesFromSeekDissolution	735000	usd
CY2021	clov	Activities From Seek Dissolution ActivitiesFromSeekDissolution	0	usd
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001801170-24-000064-index-headers.html	Edgar Link	pending
0001801170-24-000064-index.html	Edgar Link	pending
0001801170-24-000064.txt	Edgar Link	pending
0001801170-24-000064-xbrl.zip	Edgar Link	pending
a12312023-exx1016.htm	Edgar Link	pending
a12312023-exx1017.htm	Edgar Link	pending
a12312023-exx211.htm	Edgar Link	pending
a12312023-exx231.htm	Edgar Link	pending
a12312023-exx311.htm	Edgar Link	pending
a12312023-exx312.htm	Edgar Link	pending
a12312023-exx321.htm	Edgar Link	pending
a12312023-exx322.htm	Edgar Link	pending
a12312023-exx971.htm	Edgar Link	pending
clov-20231231.htm	Edgar Link	pending
clov-20231231.xsd	Edgar Link	pending
clov-20231231_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
clov-20231231_def.xml	Edgar Link	unprocessable
clov-20231231_lab.xml	Edgar Link	unprocessable
clov-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
clov-20231231_htm.xml	Edgar Link	completed
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
clov-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov

2023 Q4 Form 10-K Financial Statement

#000180117024000064 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLOV CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov

2023 Q4 Form 10-K Financial Statement

#000180117024000064 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov